Ascentage Pharma Group International FDA And EMA Clear Phase Iii Study Of Lisaftoclax For Hr-Mds
ReutersAug 18, 2025 1:17 AM
Aug 18 (Reuters) - Ascentage Pharma Group International 6855.HK:
FDA AND EMA CLEAR PHASE III STUDY OF LISAFTOCLAX FOR HR-MDS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Don't Miss Walmart's Aug 21 Earnings: $0.73 EPS Forecast, Grocery + E-Com Dual Engines – Unlimited Upside Potential?
TradingKey - Walmart's stock price has shown an overall fluctuating upward trend since the release of its first-quarter earnings report, benefiting from investors' favoritism towards Walmart as a defensive stock, as well as expectations for its stable growth in e-commerce and grocery businesses.TradingKey
22 hours ago
Eurozone Q2 GDP Commentary: Will the Euro's Upward Momentum Persist?
TradingKey - On 14 August 2025, Eurostat published Q2 GDP figures, revealing a drop in the Eurozone's quarter-on-quarter growth from 0.6% in the first quarter to 0.1%. Consequently, annual growth eased from 1.5% to 1.4%. The slowdown primarily stems from the diminishing boost from European...TradingKey
23 hours ago
Bridgewater Associates Q2 2025 13F Analysis: Founder Ray Dalio’s Final Act
TradingKey - Bridgewater Associates, the world’s largest hedge fund and renowned for its macroeconomic analysis, continues to command market respect with its “risk parity” strategy and precise economic cycle timing.TradingKey
Thu, Aug 14
What is the Future of Stablecoins? Here are Some Stablecoin Stocks to Watch
With regulations solidifying, institutional money flowing in, and global market expansion accelerating, stablecoin-related stocks could experience unprecedented growth.TradingKey
Wed, Jun 11
Tesla Q1 2025 Earning Report Review: Autonomous Driving and Robotics Lead Future Growth
TradingKey - Tesla's Q1 2025 earnings results revealed short-term financial pressure, with core data lower than market expectations, and both revenue and profitability facing challenges. Against the backdrop of sales and profit pressure, Musk remains confident in Tesla's future.TradingKey
Wed, Apr 23
